sibmedСибирский научный медицинский журналСибирский научный медицинский журнал2410-25122410-2520ИЦиГ СО РАН10.18699/SSMJ20220201sibmed-755Research ArticleОБЗОРЫREVIEWSНейровоспаление и химиоиндуцированная периферическая нейропатияNeuroinflammation and сhemotherapy-induced peripheral neuropathyПилипенкоП. И.PilipenkoP. I.

 д.м.н., проф. 

630091, г. Новосибирск, Красный просп., 52

630060, г. Новосибирск, ул. Тимакова, 2

 doctor of medical sciences, professor 

630091, Novosibirsk, Krasny ave., 52

630117, Novosibirsk, Timakov str., 2

pilipen@mail.ruВойцицкийВ. Е.VoytsitskyV. E.

 д.м.н., проф.

630091, г. Новосибирск, Красный просп., 52

 doctor of medical sciences, professor 

630091, Novosibirsk, Krasny ave., 52

v.vladimir2020@mail.ruДобрескоЮ. А.DobreskoYu. A.

630091, г. Новосибирск, Красный просп., 52

630060, г. Новосибирск, ул. Тимакова, 2

630091, Novosibirsk, Krasny ave., 52

630117, Novosibirsk, Timakov str., 2

dobresko93@inbox.ruНовосибирский государственный медицинский университет Минздрава России; ФИЦ фундаментальной и трансляционной медициныРоссияNovosibirsk State Medical University of Minzdrav of Russia; Federal Research Center of Fundamental and Translational MedicineRussian FederationНовосибирский государственный медицинский университет Минздрава РоссииРоссияNovosibirsk State Medical University of Minzdrav of RussiaRussian Federation20222004202242249Copyright © Пилипенко П.И., Войцицкий В.Е., Добреско Ю.А., 20222022Пилипенко П.И., Войцицкий В.Е., Добреско Ю.А.Pilipenko P.I., Voytsitsky V.E., Dobresko Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://sibmed.elpub.ru/jour/article/view/755

 

Нейротоксичность является одним из частых побочных эффектов противоопухолевой химиотерапии, ее распространенность составляет от 38 до 90 %. В ряде случаев данная патология не только негативно влияет на качество жизни пациентов, но и становится причиной ограничения дозы цитостатиков. Поэтому крайне актуальны задачи ранней диагностики, профилактики и лечения нейротоксичности. Чтобы разработать эффективную стратегию ее лечения на фоне химиотерапии, необходимо понимать механизмы, лежащие в основе поражения, особенно процессы нейровоспаления. Цель данного обзора – рассмотреть результаты современных исследований о влиянии химиотерапии на активность провоспалительных цитокинов. В связи с этим крайне актуально изучение поведенческих нарушений при нейропатической боли на моделях in vivo. Появляется все больше доказательств, что различные противоопухолевые препараты повышают продукцию провоспалительных цитокинов, хемокинов, вызывают повреждения дорзального ганглия или дистальных нервных окончаний. Дальнейшие исследования химиоиндуцированной периферической нейропатии с использованием животных моделей необходимы для глубокого понимания причинно-следственных механизмов ее развития и выбора новых более эффективных методов лечения.

Neurotoxicity is one of the common side effects of anticancer chemotherapy. This pathology has a detectability of 38–90%. In some cases, it causes not only a significant decrease of life quality but also decrease of dose of cytostatics. Therefore, the tasks of early diagnosis, prevention and treatment of neurotoxicity are very relevant. Sensors underlying detection, especially neuroinflammation processes, are needed to develop an effective therapy for chemotherapy-induced neurotoxicity. The purpose of this topic is to study the results of chemotherapy studies on changes in the activity of proinflammatory cytokines. In this regard, the study of behavioral societies in neuropathic pain in animal models is of great importance. It was revealed that various manifestations of inflammation of pro-inflammatory cytokines, chemokines, damage to the dorsal ganglion or distal nerve endings are increasingly being detected. Detection of chemically induced peripheral neuropathy using animal models is necessary for in-depth identification of the cause-and-effect mechanisms of its development and selection of new, more effective methods of treatment.

онкологияхимиотерапияхимиоиндуцированная периферическая нейропатияцитокинынейровоспалениеoncologychemotherapychemotherapy-induced peripheral neuropathycytokinesneuroinflammationReferencesPark S.B., Goldstein D., Krishnan A.V., Lin C.S., Friedlander M.L., Cassidy J., Koltzenburg M., Kiernan M.C. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J. Clin. 2013;63(6):419–437. doi: 10.3322/caac.21204Park S.B., Goldstein D., Krishnan A.V., Lin C.S., Friedlander M.L., Cassidy J., Koltzenburg M., Kiernan M.C. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J. Clin. 2013;63(6):419–437. doi: 10.3322/caac.21204Kerckhove N., Collin A., Condé S., Chaleteix C., Pezet D., Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front. Pharmacol. 2017;8:86. doi: 10.3389/fphar.2017.00086Kerckhove N., Collin A., Condé S., Chaleteix C., Pezet D., Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front. Pharmacol. 2017;8:86. doi: 10.3389/fphar.2017.00086Balayssac D., Ferrier J., Descoeur J., Ling B., Pezet D., Eschalier A., Authier N. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin. Drug Saf. 2011;10(3):407–417. doi: 10.1517/14740338.2011.543417Balayssac D., Ferrier J., Descoeur J., Ling B., Pezet D., Eschalier A., Authier N. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin. Drug Saf. 2011;10(3):407–417. doi: 10.1517/14740338.2011.543417Wilkes G. Peripheral neuropathy related to chemotherapy. Semin. Oncol. Nurs. 2007;23(3):162–173. doi: 10.1016/j.soncn.2007.05.001Wilkes G. Peripheral neuropathy related to chemotherapy. Semin. Oncol. Nurs. 2007;23(3):162–173. doi: 10.1016/j.soncn.2007.05.001Kerckhove N., Collin A., Condé S., Chaleteix C., Pezet D., Balayssac D., Guastella V. Neuropathies périphériques chimio-induites : symptomatologie et épidémiologie. Bull. Cancer. 2018;105(11):1020–1032. doi: 10.1016/j.bulcan.2018.07.009Kerckhove N., Collin A., Condé S., Chaleteix C., Pezet D., Balayssac D., Guastella V. Neuropathies périphériques chimio-induites : symptomatologie et épidémiologie. Bull. Cancer. 2018;105(11):1020–1032. doi: 10.1016/j.bulcan.2018.07.009Seretny M., Currie G.L., Sena E.S., Ramnarine S., Grant R., MacLeod M.R., Colvin L.A., Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461–2470. doi: 10.1016/j.pain.2014.09.020Seretny M., Currie G.L., Sena E.S., Ramnarine S., Grant R., MacLeod M.R., Colvin L.A., Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461–2470. doi: 10.1016/j.pain.2014.09.020Wang X.M., Lehky T.J., Brell J.M., Dorsey S.G. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3–9. doi: 10.1016/j.cyto.2012.03.027Wang X.M., Lehky T.J., Brell J.M., Dorsey S.G. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3–9. doi: 10.1016/j.cyto.2012.03.027Scholz J., Woolf C.J. The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 2007;10(11):1361–1368. doi: 10.1038/nn1992Scholz J., Woolf C.J. The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 2007;10(11):1361–1368. doi: 10.1038/nn1992Gornstein E., Schwarz T.L. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology. 2014;76(A):175–183. doi: 10.1016/j.neuropharm.2013.08.016Gornstein E., Schwarz T.L. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology. 2014;76(A):175–183. doi: 10.1016/j.neuropharm.2013.08.016Argyriou A.A., Bruna J., Marmiroli P., Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit. Rev. Oncol. Hematol. 2012;82(1):51–77. doi: 10.1016/j.critrevonc.2011.04.012Argyriou A.A., Bruna J., Marmiroli P., Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit. Rev. Oncol. Hematol. 2012;82(1):51–77. doi: 10.1016/j.critrevonc.2011.04.012Boyette-Davis J., Xin W., Zhang H., Dougherty P.M. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain. 2011;152(2):308–313. doi: 10.1016/j.pain.2010.10.030Boyette-Davis J., Xin W., Zhang H., Dougherty P.M. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain. 2011;152(2):308–313. doi: 10.1016/j.pain.2010.10.030LaPointe N.E., Morfini G., Brady S.T., Feinstein S.C., Wilson L., Jordan M.A. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013; 37, 231–239. doi: 10.1016/j.neuro.2013.05.008LaPointe N.E., Morfini G., Brady S.T., Feinstein S.C., Wilson L., Jordan M.A. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013; 37, 231–239. doi: 10.1016/j.neuro.2013.05.008Loprinzi C.L., Reeves B.N., Dakhil S.R., Sloan J.A., Wolf S.L., Burger K.N., Kamal A., LeLindqwister N.A., Soori G.S., Jaslowski A.J., Novotny P.J., Lachance D.H. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J. Clin. Oncol. 2011 10;29(11):1472–1478. doi: 10.1200/JCO.2010.33.0308Loprinzi C.L., Reeves B.N., Dakhil S.R., Sloan J.A., Wolf S.L., Burger K.N., Kamal A., LeLindqwister N.A., Soori G.S., Jaslowski A.J., Novotny P.J., Lachance D.H. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J. Clin. Oncol. 2011 10;29(11):1472–1478. doi: 10.1200/JCO.2010.33.0308Dina O.A., Chen X., Reichling D., Levine J.D. Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience. 2001;108(3):507–515. doi: 10.1016/s0306-4522(01)00425-0Dina O.A., Chen X., Reichling D., Levine J.D. Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience. 2001;108(3):507–515. doi: 10.1016/s0306-4522(01)00425-0Peters C.M., Jimenez-Andrade J.M., Jonas B.M., Sevcik M.A., Koewler N.J., Ghilardi J.R., Wong G.Y., Mantyh P.W. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp. Neurol. 2007;203(1):42–54. doi: 10.1016/j.expneurol.2006.07.022Peters C.M., Jimenez-Andrade J.M., Jonas B.M., Sevcik M.A., Koewler N.J., Ghilardi J.R., Wong G.Y., Mantyh P.W. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp. Neurol. 2007;203(1):42–54. doi: 10.1016/j.expneurol.2006.07.022Peters C.M., Jimenez-Andrade J.M., Kuskowski M.A., Ghilardi J.R., Mantyh P.W. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res. 2007;1168:46–59. doi: 10.1016/j.brainres.2007.06.066Peters C.M., Jimenez-Andrade J.M., Kuskowski M.A., Ghilardi J.R., Mantyh P.W. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res. 2007;1168:46–59. doi: 10.1016/j.brainres.2007.06.066Holland S.D., Ramer L.M., McMahon S.B., Denk F., Ramer M.S. An ATF3-CreERT2 Knock-in mouse for axotomy-induced genetic editing: proof of principle. eNeuro. 2019;6(2):ENEURO.0025-19.2019. doi: 10.1523/ENEURO.0025-19.2019Holland S.D., Ramer L.M., McMahon S.B., Denk F., Ramer M.S. An ATF3-CreERT2 Knock-in mouse for axotomy-induced genetic editing: proof of principle. eNeuro. 2019;6(2):ENEURO.0025-19.2019. doi: 10.1523/ENEURO.0025-19.2019Brandolini L., d’Angelo M., Antonosante A., Allegretti M., Cimini A. Chemokine signaling in chemotherapy-induced neuropathic pain. Int. J. Mol. Sci. 2019;20(12):2904. doi: 10.3390/ijms20122904Brandolini L., d’Angelo M., Antonosante A., Allegretti M., Cimini A. Chemokine signaling in chemotherapy-induced neuropathic pain. Int. J. Mol. Sci. 2019;20(12):2904. doi: 10.3390/ijms20122904Lees J.G., Makker P.G., Tonkin R.S., Abdulla M., Park S.B., Goldstein D., Moalem-Taylor G. Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur. J. Cancer. 2017;73:22–29. doi: 10.1016/j.ejca.2016.12.006Lees J.G., Makker P.G., Tonkin R.S., Abdulla M., Park S.B., Goldstein D., Moalem-Taylor G. Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. Eur. J. Cancer. 2017;73:22–29. doi: 10.1016/j.ejca.2016.12.006Javeed A., Ashraf M., Riaz A., Ghafoor A., Afzal S., Mukhtar M.M. Paclitaxel and immune system. Eur. J. Pharm. Sci. 2009;38(4):283–290. doi: 10.1016/j.ejps.2009.08.009Javeed A., Ashraf M., Riaz A., Ghafoor A., Afzal S., Mukhtar M.M. Paclitaxel and immune system. Eur. J. Pharm. Sci. 2009;38(4):283–290. doi: 10.1016/j.ejps.2009.08.009Warwick R.A., Hanani M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur. J. Pain. 2013;17(4):571–580. doi: 10.1002/j.1532-2149.2012.00219.xWarwick R.A., Hanani M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur. J. Pain. 2013;17(4):571–580. doi: 10.1002/j.1532-2149.2012.00219.xFumagalli G., Monza L., Cavaletti G., Rigolio R., Meregalli C. Neuroinflammatory process involved in different preclinical models of chemotherapy-induced peripheral neuropathy. Front. Immunol. 2021;11:626687. doi: 10.3389/fimmu.2020.626687Fumagalli G., Monza L., Cavaletti G., Rigolio R., Meregalli C. Neuroinflammatory process involved in different preclinical models of chemotherapy-induced peripheral neuropathy. Front. Immunol. 2021;11:626687. doi: 10.3389/fimmu.2020.626687Jessen K.R., Mirsky R. The success and failure of the schwann cell response to nerve injury. Front. Cell Neurosci. 2019;13:33. doi: 10.3389/fncel.2019.00033Jessen K.R., Mirsky R. The success and failure of the schwann cell response to nerve injury. Front. Cell Neurosci. 2019;13:33. doi: 10.3389/fncel.2019.00033Bolin L.M., Verity A.N., Silver J.E., Shooter E.M., Abrams J.S. Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. J. Neurochem. 1995;64(2):850–858. doi: 10.1046/j.1471-4159.1995.64020850.xBolin L.M., Verity A.N., Silver J.E., Shooter E.M., Abrams J.S. Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. J. Neurochem. 1995;64(2):850–858. doi: 10.1046/j.1471-4159.1995.64020850.xMuja N., DeVries G.H. Prostaglandin E(2) and 6-keto-prostaglandin F(1alpha) production is elevated following traumatic injury to sciatic nerve. Glia. 2004;46(2):116–129. doi: 10.1002/glia.10349Muja N., DeVries G.H. Prostaglandin E(2) and 6-keto-prostaglandin F(1alpha) production is elevated following traumatic injury to sciatic nerve. Glia. 2004;46(2):116–129. doi: 10.1002/glia.10349Shamash S., Reichert F., Rotshenker S. The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta. J. Neurosci. 2002;22(8):3052–3060. doi: 10.1523/JNEUROSCI.22-08-03052.2002Shamash S., Reichert F., Rotshenker S. The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta. J. Neurosci. 2002;22(8):3052–3060. doi: 10.1523/JNEUROSCI.22-08-03052.2002Gao Y.J., Ji R.R. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol. Ther. 2010;126(1):56–68. doi: 10.1016/j.pharmthera.2010.01.002Gao Y.J., Ji R.R. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol. Ther. 2010;126(1):56–68. doi: 10.1016/j.pharmthera.2010.01.002Milligan E., Zapata V., Schoeniger D., Chacur M., Green P., Poole S., Martin D., Maier S.F., Watkins L.R. An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur. J. Neurosci. 2005;22(11):2775–2782. doi: 10.1111/j.1460-9568.2005.04470.xMilligan E., Zapata V., Schoeniger D., Chacur M., Green P., Poole S., Martin D., Maier S.F., Watkins L.R. An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur. J. Neurosci. 2005;22(11):2775–2782. doi: 10.1111/j.1460-9568.2005.04470.xLeo M., Schmitt L.I., Kutritz A., Kleinschnitz C., Hagenacker T. Cisplatin-induced activation and functional modulation of satellite glial cells lead to cytokine-mediated modulation of sensory neuron excitability. Exp. Neurol. 2021;341:113695. doi: 10.1016/j.expneurol.2021.113695Leo M., Schmitt L.I., Kutritz A., Kleinschnitz C., Hagenacker T. Cisplatin-induced activation and functional modulation of satellite glial cells lead to cytokine-mediated modulation of sensory neuron excitability. Exp. Neurol. 2021;341:113695. doi: 10.1016/j.expneurol.2021.113695Zajączkowska R., Kocot-Kępska M., Leppert W., Wrzosek A., Mika J., Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 2019;20(6):1451. doi: 10.3390/ijms20061451Zajączkowska R., Kocot-Kępska M., Leppert W., Wrzosek A., Mika J., Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 2019;20(6):1451. doi: 10.3390/ijms20061451da Costa R., Passos G.F., Quintão N.L.M., Fernandes E.S., Maia J.R., Campos M.M., Calixto J.B. Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives. Br. J. Pharmacol. 2020;177(14):3127–3146. doi: 10.1111/bph.15086da Costa R., Passos G.F., Quintão N.L.M., Fernandes E.S., Maia J.R., Campos M.M., Calixto J.B. Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives. Br. J. Pharmacol. 2020;177(14):3127–3146. doi: 10.1111/bph.15086Sh Q., Cai X., Shi G., Lv X., Yu J., Wang F. Interleukin-4 protects from chemotherapy-induced peripheral neuropathy in mice modal via the stimulation of IL-4/STAT6 signaling. Acta Cir. Bras. 2018;33(6):491–498. doi: 10.1590/s0102-865020180060000003Sh Q., Cai X., Shi G., Lv X., Yu J., Wang F. Interleukin-4 protects from chemotherapy-induced peripheral neuropathy in mice modal via the stimulation of IL-4/STAT6 signaling. Acta Cir. Bras. 2018;33(6):491–498. doi: 10.1590/s0102-865020180060000003Singh G., Singh A., Singh P., Bhatti R. Bergapten ameliorates vincristine-induced peripheral neuropathy by inhibition of inflammatory cytokines and NFκB signaling. ACS Chem. Neurosci. 2019;10(6):3008–3017. doi: 10.1021/acschemneuro.9b00206Singh G., Singh A., Singh P., Bhatti R. Bergapten ameliorates vincristine-induced peripheral neuropathy by inhibition of inflammatory cytokines and NFκB signaling. ACS Chem. Neurosci. 2019;10(6):3008–3017. doi: 10.1021/acschemneuro.9b00206Burmeister A.R., Johnson M.B., Marriott I. Murine astrocytes are responsive to the pro-inflammatory effects of IL-20. Neurosci. Lett. 2019;708:134334. doi: 10.1016/j.neulet.2019.134334Burmeister A.R., Johnson M.B., Marriott I. Murine astrocytes are responsive to the pro-inflammatory effects of IL-20. Neurosci. Lett. 2019;708:134334. doi: 10.1016/j.neulet.2019.134334Chen L.H., Yeh Y.M., Chen Y.F., Hsu Y.H., Wang H.H., Lin P.C., Chang L.Y., Lin C.K., Chang M.S., Shen M.R. Targeting interleukin-20 alleviates paclitaxel-induced peripheral neuropathy. Pain. 2020;161(6):1237–1254. doi: 10.1097/j.pain.0000000000001831Chen L.H., Yeh Y.M., Chen Y.F., Hsu Y.H., Wang H.H., Lin P.C., Chang L.Y., Lin C.K., Chang M.S., Shen M.R. Targeting interleukin-20 alleviates paclitaxel-induced peripheral neuropathy. Pain. 2020;161(6):1237–1254. doi: 10.1097/j.pain.0000000000001831Meregalli C., Monza L., Chiorazzi A., Scali C., Guarnieri C., Fumagalli G., Alberti P., Pozzi E., Canta A., Ballarini E., … Marmiroli P. Human intravenous immunoglobulin alleviates neuropathic symptoms in a rat model of paclitaxel-induced peripheral neurotoxicity. Int. J. Mol. Sci. 2021;22(3):1058. doi: 10.3390/ijms22031058Meregalli C., Monza L., Chiorazzi A., Scali C., Guarnieri C., Fumagalli G., Alberti P., Pozzi E., Canta A., Ballarini E., … Marmiroli P. Human intravenous immunoglobulin alleviates neuropathic symptoms in a rat model of paclitaxel-induced peripheral neurotoxicity. Int. J. Mol. Sci. 2021;22(3):1058. doi: 10.3390/ijms22031058Zhang H., Li Y., de Carvalho-Barbosa M., Kavelaars A., Heijnen C.J., Albrecht P.J., Dougherty P.M. Dorsal root ganglion infiltration by macrophages contributes to paclitaxel chemotherapy-induced peripheral neuropathy. J. Pain. 2016;17(7):775–786. doi: 10.1016/j.jpain.2016.02.011Zhang H., Li Y., de Carvalho-Barbosa M., Kavelaars A., Heijnen C.J., Albrecht P.J., Dougherty P.M. Dorsal root ganglion infiltration by macrophages contributes to paclitaxel chemotherapy-induced peripheral neuropathy. J. Pain. 2016;17(7):775–786. doi: 10.1016/j.jpain.2016.02.011Navia-Pelaez J.M., Choi S.H., Capettini S.A.L., Xia Y., Gonen A., Agatisa-Boyle C., Delay .L, dos Santos G.G., Catroli G.F., Kim J., … Miller Y.I. Normalization of cholesterol metabolism in spinal microglia alleviates neuropathic pain. J. Exp. Med. 2021;218(7):e20202059. doi: 10.1084/jem.20202059Navia-Pelaez J.M., Choi S.H., Capettini S.A.L., Xia Y., Gonen A., Agatisa-Boyle C., Delay .L, dos Santos G.G., Catroli G.F., Kim J., … Miller Y.I. Normalization of cholesterol metabolism in spinal microglia alleviates neuropathic pain. J. Exp. Med. 2021;218(7):e20202059. doi: 10.1084/jem.20202059

The authors declare that there are no conflicts of interest present.